Edition:
United Kingdom

Cytosorbents Corp (CTSO.OQ)

CTSO.OQ on NASDAQ Stock Exchange Capital Market

7.70USD
20 Apr 2018
Change (% chg)

$-0.05 (-0.65%)
Prev Close
$7.75
Open
$7.75
Day's High
$7.80
Day's Low
$7.68
Volume
5,084
Avg. Vol
22,122
52-wk High
$8.32
52-wk Low
$3.35

Chart for

About

CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company's purification technologies are based on biocompatible, porous polymer beads... (more)

Overall

Beta: -0.59
Market Cap(Mil.): $173.02
Shares Outstanding(Mil.): 28.13
Dividend: --
Yield (%): --

Financials

  CTSO.OQ Industry Sector
P/E (TTM): -- 148.40 32.74
EPS (TTM): -0.37 -- --
ROI: -77.87 9.37 14.38
ROE: -162.40 14.69 16.07

BRIEF-Cytosorbents Refinances Existing Debt With New $15 Mln Debt Facility With Bridge Bank

* CYTOSORBENTS REFINANCES EXISTING DEBT WITH NEW $15 MILLION DEBT FACILITY WITH BRIDGE BANK

04 Apr 2018

BRIEF-Cytosorbents Achieves Record Revenue And Product Sales Growth In 2017

* CYTOSORBENTS ACHIEVES RECORD REVENUE AND PRODUCT SALES GROWTH IN 2017

08 Mar 2018

BRIEF-Cytosorbents Expands Its Partnership With Biocon To Launch Cytosorb In Malaysia

* CYTOSORBENTS EXPANDS ITS PARTNERSHIP WITH BIOCON TO LAUNCH CYTOSORB® IN MALAYSIA

15 Feb 2018

BRIEF-Cytosorbents Sees Q4 2017 Revenue About $4.6 Million

* CYTOSORBENTS PRE-ANNOUNCES PRELIMINARY FOURTH QUARTER AND FULL YEAR 2017 RESULTS AND ISSUES STOCKHOLDER LETTER

08 Jan 2018

BRIEF-U.S. FDA Approves Cytosorbents' Refresh 2 IDE Application With Conditions

* CYTOSORBENTS ACHIEVES KEY MILESTONE WITH FDA APPROVAL OF THE U.S. REFRESH 2 PIVOTAL CARDIAC SURGERY TRIAL IDE APPLICATION

21 Dec 2017

BRIEF-Cytosorbents posts Q3 revenue of $3.8 mln

* Cytosorbents continues strong trajectory of growth in the third quarter 2017

09 Nov 2017

Competitors

Earnings vs. Estimates